OnCo
companiesCompany

ImmunityBio

ImmunityBio makes Anktiva, the IL-15 superagonist approved with BCG for bladder cancer in 2024.

Nogapendekin alfa inbakicept (Anktiva); NK-cell and vaccine programmes; long regulatory path including a 2023 CRL.

Headquarters
San Diego, CA, US
Type
biotech · IBRX

Products

1top
ApprovedIL-15 superagonist (intravesical, with BCG)
Nogapendekin alfa inbakicept · Anktiva

Nogapendekin alfa inbakicept is an engineered version of the immune-boosting protein IL-15, given with BCG into the bladder, approved in 2024 for early bladder cancer that BCG alone no longer controls.

Connected

4top

cancers

1
Bladder & urothelial cancer

fronts

1
Immunotherapy

drugs

1
ApprovedIL-15 superagonist (intravesical, with BCG)
Nogapendekin alfa inbakicept · Anktiva

ideas

1
Off-the-shelf natural killer cells to sweep up residual disease